Published Data Show Why GSK Bailed on Its Maternal RSV Vaccine

(MedPage Today) -- GSK's abandoned maternal respiratory syncytial virus (RSV) vaccine protected infants from severe RSV, final results of a phase III trial indicated, but those positive outcomes came at the expense of an unexplained higher risk...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news